APA (7th ed.) Citation

F, S., K, G., CLBM, K., KA, F., I, K., S, K., . . . NWCJ, v. d. D. (2026). Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab. Blood cancer journal, 16(1), . https://doi.org/10.1038/s41408-026-01451-9

Chicago Style (17th ed.) Citation

F, Smits, et al. "Immunoglobulin Supplementation and Longer Dosing Intervals Reduce Risk of Infections in Patients with RRMM Treated with Teclistamab." Blood Cancer Journal 16, no. 1 (2026). https://doi.org/10.1038/s41408-026-01451-9.

MLA (9th ed.) Citation

F, Smits, et al. "Immunoglobulin Supplementation and Longer Dosing Intervals Reduce Risk of Infections in Patients with RRMM Treated with Teclistamab." Blood Cancer Journal, vol. 16, no. 1, 2026, https://doi.org/10.1038/s41408-026-01451-9.